Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience.
Fiche publication
Date publication
janvier 2019
Journal
Therapeutic advances in gastroenterology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
D'Amico F, Parigi TL, Fiorino G, Peyrin-Biroulet L, Danese S
Lien Pubmed
Résumé
Tofacitinib is an oral small molecule directed against the JAK/STAT pathway, blocking the inflammatory cascade. Oral formulation of tofacitinib has recently been approved for the treatment of patients with moderate-severe ulcerative colitis. Its efficacy and safety have been demonstrated in three phase III clinical trials and confirmed by promising real-life data. The purpose of this review is to summarize the available evidence on the efficacy and safety of tofacitinib and to define its role and position in the treatment algorithms for patients with ulcerative colitis.
Mots clés
real-world experience, tofacitinib, ulcerative colitis
Référence
Therap Adv Gastroenterol. 2019 ;12:1756284819848631